These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1794136)

  • 21. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
    Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
    Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barrett's oesophagus: from metaplasia to dysplasia and cancer.
    Fléjou JF
    Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i6-12. PubMed ID: 15711008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1.
    Brändlein S; Beyer I; Eck M; Bernhardt W; Hensel F; Müller-Hermelink HK; Vollmers HP
    Cancer Res; 2003 May; 63(9):2052-61. PubMed ID: 12727819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
    Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
    Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role of minichromosome maintenance protein 2 as a screening biomarker in esophageal cancer high-risk population in China.
    Huang B; Hu B; Su M; Tian D; Guo Y; Lian S; Liu Z; Wu X; Li Q; Zheng R; Gao Y
    Hum Pathol; 2011 Jun; 42(6):808-16. PubMed ID: 21237484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barrett's esophagus and Barrett's-related dysplasia.
    Goldblum JR
    Mod Pathol; 2003 Apr; 16(4):316-24. PubMed ID: 12692197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Barrett's esophagus and risk of esophageal adenocarcinoma.
    Cossentino MJ; Wong RK
    Semin Gastrointest Dis; 2003 Jul; 14(3):128-35. PubMed ID: 14653412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
    Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
    Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histology of metaplasia and dysplasia in Barrett's esophagus.
    Yerian L
    Surg Oncol Clin N Am; 2009 Jul; 18(3):411-22. PubMed ID: 19500733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoplastic precursor lesions in Barrett's esophagus.
    Hornick JL; Odze RD
    Gastroenterol Clin North Am; 2007 Dec; 36(4):775-96, v. PubMed ID: 17996790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical management of Barrett's esophagus.
    Clark GW; DeMeester TR
    Ann Chir Gynaecol; 1995; 84(2):139-44. PubMed ID: 7574371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett's oesophagus patients at risk for malignant transformation.
    Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
    J Pathol; 2006 Jan; 208(1):100-7. PubMed ID: 16278815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer risk in Barrett's oesophagus.
    Dias Pereira A; Suspiro A; Chaves P
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):915-8. PubMed ID: 18049157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus.
    Buskens CJ; Hulscher JB; van Gulik TM; Ten Kate FJ; van Lanschot JJ
    J Surg Res; 2006 Oct; 135(2):337-44. PubMed ID: 16926029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro.
    De Gottardi A; Dumonceau JM; Bruttin F; Vonlaufen A; Morard I; Spahr L; Rubbia-Brandt L; Frossard JL; Dinjens WN; Rabinovitch PS; Hadengue A
    Mol Cancer; 2006 Oct; 5():48. PubMed ID: 17054793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.